Projects
Search from 1147 projects:
1147 Project(s)
INCMOR0208-301: A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBOCONTROLLED, MULTICENTER TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF TAFASITAMAB PLUS LENALIDOMIDE IN ADDITION TO RITUXIMAB VERSUS LENALIDOMIDE IN ADDITION TO RITUXIMAB IN PATIENTS WITH RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL) GRADE 1-3A OR R/R MARGINA
Apr 20, 2022Doppel-blind, Placebo-kontrollierte, randomisierte Phase 3 Studie zur Evaluation eines zusätzlichen klinischen Benefits durch die Zugabe des CD19-Antikörpers Tafasitamab zu Rituximab-Lenalidomid bei Patienten mit rezidiviertem/refraktärem Follikuläre...
Clinical Studies - Apr 20, 2022 - Dec 31, 2025
Ongoing
Project leader: Fehr Martin
Members: Bürki Ramona
MitraSwiss Register
Apr 1, 2022A longitudinal observational study of patients treated with the MitraClip system in Switzerland
Register - Apr 1, 2022 - Dec 31, 2030
Ongoing
Project leader: Haager Philipp
Members: Schneider Irene
ADDRESS
Mar 25, 2022Weight Loss and Treatment Patterns in a Real-World Population of Adults Receiving Saxenda® for Weight Management in Routine Clinical Practice in Switzerland
Clinical Studies - Mar 25, 2022 - Jun 30, 2022
Completed
Project leader: Aczel Stefan
Members: Räss Andrea
Metabotropic Glutamate Receptor 5 Imaging in Amyotrophic Lateral Sclerosis (ALS) Using Positron Emission Tomography (PET)
Mar 24, 2022Amyotrophic lateral sclerosis is a fatal neurodegenerative disorder characterized by a progressive and selective loss of upper and lower motor neurons (MNs), causing weakness and ultimately death. Glutamate excitotoxicity has been suggested to play a...
Clinical Studies - Mar 24, 2022 - Nov 30, 2025
Ongoing
Project leader: Braun Nathalie
SNIP-Test in patients with Amyotrophic Lateral sclerosis: How many does it need?”
Mar 20, 2022Amyotrophe Lateralsklerose (ALS) ist eine schwere neurologische Erkrankung bei der es zum Untergang derjenigen Nervenzellen kommt, die für die Bewegung verantwortlich sind. Deshalb kommt es unter anderem zu einem Muskelschwund und dem Verlust der Kr...
Clinical Studies - Mar 20, 2022 - Mar 20, 2024
Aborted
Project leader: Weber Markus
Members: Burkhardt Christian, Czell David
Integrative analysis for the delineation of cellular crosstalk in glioblastoma
Mar 4, 2022
Fundamental Research - Mar 4, 2022 - Dec 31, 2023
Automatically Closed
Project leader: Neidert Marian C, Buljan Marija
ANV419 Single Agent (Parts A-C) or Combination (Part D) First in Human Study Phase 1/2: Open-label, Dose Escalation and Expansion Study in Patients with Relapsed/Refractory Advanced Solid Tumors and Multiple Myeloma. (Anaveon)
Mar 3, 2022Diese klinische Studie wird durchgeführt, um ein neues Arzneimittel mit dem Namen ANV419 zu testen. Dieses neue Arzneimittel hat im menschlichen Körper eine Wirkung ähnlich Interleukin-2. Diese klinische Studie wird durchgeführt, um die Sicherheit...
Clinical Studies - Mar 3, 2022 - Mar 2, 2024
Automatically Closed
Project leader: Jörger Markus
Members: Wittwer Yvonne, Quinter Janine
A Phase III, randomised, Open-Label, multicenter study evaluating the efficacy and safety of adjuvant GDC-9545 compared with physician's choice of adjuvant endocrine Monotherapy in patiens with Estrogen Receptor−Positive, HER2-NegativeEarly Breat Cancer
Mar 1, 2022Der Zweck dieser Studie ist es, die positiven oder negativen Auswirkungen von Giredestrant im Vergleich zu einer zugelassenen endokrinen Therapie (eine Behandlung, die Hormone blockiert oder entfernt) bei Patientinnen/Patienten mit Ihrer Art von Kreb...
Clinical Studies - Mar 1, 2022 - Jul 26, 2030
Ongoing
Project leader: Huober Jens
Members: Sennhauser Andrina, Quinter Janine
Symptoms compatible with long-COVID in SARS-CoV-2 positive and negative healthcare workers – analysis of prospective cohort data
Mar 1, 2022In this analysis, we are aiming to determine the impact of viral variant and of vaccination on the occurence and the temporal dynamics of long COVID symptoms in healthcare workers.
Healthcare Research - Mar 1, 2022 - Dec 31, 2022
Automatically Closed
Project leader: Kohler Philipp
MT-1186-A02
Feb 14, 2022Eine Studie zur Untersuchung, ob die Prüfsubstanz Edaravone, die als flüssige Lösung zum Schlucken über einen Zeitraum von 48 Wochen verabreicht wird, bei Patienten mit ALS gut wirkt und sicher ist.
Clinical Studies - Feb 14, 2022 - Dec 31, 2024
Ongoing
Project leader: Braun Nathalie
Real world utilization of upadacitinib in adult and adolescent patients living with moderate to severe atopic dermatitis (AD-VISE)
Feb 14, 2022
Clinical Studies - Feb 14, 2022 - Dec 31, 2025
Ongoing
Project leader: Cozzio Antonio
Eine Phase 3, multizentrische, doppelblinde, randomisierte, Plazebo-kontrollierte Studie zur Beurteilung der Wirksamkeit und Sicherheit von Reldesemtiv bei Patienten mit Amyotropher Lateralsklerose (ALS)
Jan 28, 2022Reldesemtiv, a fast skeletal muscle troponin activator (FSTA), is being investigated as a potential therapy to slow the decline of skeletal muscle function in patients with ALS. This pivotal trial with reldesemtiv is being conducted in ALS patients a...
Clinical Studies - Jan 28, 2022 - Mar 28, 2023
Automatically Closed
A phase II, open label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel Cell Carcinoma progressing on anti-PD-(L)1 antibody therapy – the MERKLIN 2 study
Jan 25, 2022
Clinical Studies - Jan 25, 2022 - Jan 25, 2022
Automatically Closed
Project leader: Cozzio Antonio
BMS_IM101-863
Jan 24, 2022A Phase 3, Randomized, Head-to-head, Single-blind Study to Compare the Response to Treatment with Subcutaneous Abatacept vs Adalimumab, on Background Methotrexate, in Adults with Early, Seropositive Rheumatoid Arthritis Who Have "Shared Epitope" HLA...
Clinical Studies - Jan 24, 2022 - Jan 17, 2025
Completed
Project leader: Rubbert-Roth Andrea
Members: Peischl Shirin, Peischl Riana, Bartz-Batliner Mira, Haller Christoph, Pirker Ian, Hutz Carina Liane
Analysis of the effect of biological therapy on SARS-CoV-2-specific antibody levels following booster vaccination in patients with inflammatory bowel disease
Jan 20, 2022This is a national multi-center cohort confirmatory study which is designed as a prospective observational trial combined with retrospective data collection. Prospective data are collected through a patient questionnaire and assessment of blood sam...
Clinical Studies - Jan 20, 2022 - Mar 30, 2023
Automatically Closed
Project leader: Brand Stephan
Members: König Marius, Dütschler Joel, Krieger-Grübel Claudia, Eckhold Annika, Truniger Samuel, Frei Nicola Fabian, Albrich Werner
A multicenter, prospective observational RWE study to assess Patient-reported wellbeing using tildrakizumab in a live setting – POSITIVE Study
Jan 18, 2022
Clinical Studies - Jan 18, 2022 - Dec 31, 2024
Ongoing
Project leader: Saulite Ieva
A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, PK, and Efficacy of MK-1084 as Monotherapy and in Combination with Pembrolizumab in Subjects with KRASG12C Mutant Advanced Solid Tumors
Jan 13, 2022MK-1084 enthält einen chemischen Wirkstoff und hemmt gezielt das mutierte KRAS-G12C-Protein. Generell spielen RAS-Proteine in der Zellteilung und Zelldifferenzierung eine grosse Rolle und wenn diese Proteine zu stark aktiviert sind, kann das zu Krebs...
Clinical Studies - Jan 13, 2022 - Mar 2, 2027
Ongoing
Project leader: Weindler Susanne
Members: Donno Monica, Quinter Janine
Transkutane tibiale Nervenstimulation zur Behandlung von neurogenen Harnblasenfunktionsstörungen
Jan 13, 2022
Clinical Studies - Jan 13, 2022 - Feb 29, 2024
Automatically Closed
SOS AMI Selatogrel
Jan 10, 2022Multi-center, double-blind, randomized, placebo-controlled, parallel-group study to evaluate the efficacy and safety of self-administered subcutaneous selatogrel for prevention of all-cause death and treatment of acute myocardial infarction in subjec...
Clinical Studies - Jan 10, 2022 - Jan 14, 2026
Ongoing
Project leader: Maeder Micha
Members: Vetsch Susanne, Fink Karin
Courage-ALS
Jan 6, 2022Die Prüfsubstanz Reldesemtiv ist ein Aktivator des schnellen Skelettmuskel-Troponin-Komplexes. Die Therapie dient zur Verbesserung der Skelettmuskelfunktion bei Erkrankungen im Zusammenhang mit Muskelschwäche und/oder Muskelermüdung.
Clinical Studies - Jan 6, 2022 - Dec 31, 2024
Ongoing
Project leader: Weber Markus